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Objectives: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been proposed to be a
potential new therapeutic target for treatment of hypercholesterolaemia. However, little is known about
the effects of PCSK9 inhibition on the lipidome.
Methods: We performed molecular lipidomic analyses of plasma samples obtained from PCSK9-deﬁcient
mice, and serum of human carriers of a loss-of-function variant in the PCSK9 gene (R46L).
Results: In both mouse and man, PCSK9 deﬁciency caused a decrease in several cholesteryl esters (CE)
and short fatty acid chain containing sphingolipid species such as CE 16:0, glucosyl/galactosylceramide
(Glc/GalCer) d18:1/16:0, and lactosylceramide (LacCer) d18:1/16:0. In mice, the changes in lipid con-
centrations were most prominent when animals were given regular chow diet. In man, a number of
molecular lipid species was shown to decrease signiﬁcantly even when LDL-cholesterol was non-
signiﬁcantly reduced by 10% only. Western diet attenuated the lipid lowering potency of PCSK9 deﬁ-
ciency in mice.
Conclusions: Plasma molecular lipid species may be utilized for characterizing novel compounds inhib-
iting PCSK9 and as sensitive efﬁcacy markers of the PCSK9 inhibition.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Plasma low-density lipoprotein cholesterol (LDL-C) is an estab-
lished risk factor for coronary artery disease (CAD). Generally, high
blood cholesterol levels are treated with statins. However, in some
patients, LDL-C treatment goals are not achieved with statins alone
and in other patients, aggressive treatment may cause intolerableginkuja 1, FI-02150 Espoo,
reijo.laaksonen@helsinki.ﬁ
nd Ltd. Open access under CC BY-NCmuscular side effects [1,2]. Thus, new LDL-C lowering methods are
needed for efﬁcient treatment of hypercholesterolaemia.
It has been shown that proprotein convertase subtilisin/kexin
type 9 (PCSK9) plays a central role in the regulation of plasma LDL-
C levels [3]. PCSK9, which belongs to a family of serine proteases,
the proprotein convertases [4], decreases the availability of LDL
receptors (LDLR) expressed on the hepatocyte surface by facili-
tating their lysosomal degradation [5]. Intriguingly, individuals
with loss-of-function mutations in the PCSK9 gene have reduced
plasma LDL-C levels and also have lower risk for CAD [6e8].
Interestingly, even a modest LDL-C reduction seems to confer
signiﬁcant cardiovascular protection on the loss-of-function-ND license.
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have been shown to be associated with elevated plasma LDL-C
levels and premature CAD [3]. These observations have posi-
tioned PCSK9 as a potential target in the treatment of hyper-
cholesterolaemia [9].
Some unexpected effects of PCSK9 in lipid and lipoprotein
metabolism including increased apoB synthesis and triglyceride
secretion have been recorded in the transgenic mouse model [10].
Thus, we assumed that the effect of PCSK9 inhibition may not be
limited only to LDL-C and applied a sophisticated molecular lip-
idomics workﬂow to investigate the effect of PCSK9 deﬁciency on
plasma lipidomes both in mice and humans in order to identify
characteristic molecular lipid changes of PCSK9 inhibition. Based on
the results of this study we propose that distinct molecular lipid
species rather than LDL-C may serve as speciﬁc efﬁcacy readout for
PCSK9 inhibitors and potentially serve also as indicators of off-
target effects.2. Materials
2.1. Animals and treatments
All the procedures were approved by the bioethics committee
for animal care of Clinical Research Institute of Montreal. C57BL/
6 wild-type (Wt) mice were obtained from the Jackson Labora-
tory. The hepatocyte-speciﬁc PCSK9 homozygote knock-out
(Pcsk9/) and PCSK9 heterozygote knock-out (Pcsk9þ/) ani-
mals mice were generated as described earlier [11]. Each group
had 18 male mice aged 3 months. Mice were ﬁrst on regular
chow (2018 Teklad Global, Harlan Laboratories) diet for two
weeks after which three mice from each group were sacriﬁced
for another study on tissue lipidomics (day 15). The remaining
mice were switched to standard Western (TD.88137 Harlan
Teklad) diet for a period of two weeks (day 30). The Western diet
contained 34%, 21%, and 0.2% of sugar, fat, and cholesterol,
respectively, whereas the regular chow diet contained 5%, 6%,
and 0% of these ingredients.2.2. Mouse sample preparation
Mice were kept fasted for 4 h before bleeding. Cheek bleeds of
about 250 ml were drawn using the 500 ml microcontainers (BD)
containing EDTA. The blood samples were centrifuged at 3000 rpm
for 15min at 4 C. The supernatants (50e100 ml) were transferred to
clean Eppendorf tubes. The samples were frozen immediately upon
sampling and stored at 80 C prior to lipidomic analyses.2.3. Clinical samples
To investigate the translation frommouse toman, human serum
samples obtained from the participants of the Ludwigshafen Risk
and Cardiovascular Health (LURIC) Study (n ¼ 988) were analysed
for molecular lipids. LURIC is an ongoing prospective study of
environmental, biochemical, and genetic risk factors for CAD in a
hospital-based cohort of Caucasians [12]. The study was approved
by the institutional review board at the "Ärztekammer Rheinland-
Pfalz". Informed written consent was obtained from each of the
participants. LURIC study subjects have earlier been genotyped on
the Affymetrics 6.0 array. We pulled out PSCK9 genotypic data for
the known loss-of-function mutation (rs 11591147, R46L) [3] from
the LURIC database (n ¼ 22).3. Methods
3.1. Lipid extraction
For Shotgun lipidomic analyses 10 ml of mouse plasma (n ¼ 1 per
sample) was used for lipid extraction. For quantiﬁcation of ceram-
ides and cerebrosides 50 ml of mouse plasma (n ¼ 1) was used lipid
extraction. Brieﬂy, lipids were extracted using a modiﬁed Folch lipid
extraction [13] performed on a Hamilton Microlab Star robot
(Hamilton Robotics, Switzerland) [14]. Samples were spiked with
known amounts of non-endogeneous synthetic internal standards
purchased from Larodan Fine Chemicals, Avanti Polar Lipids,
Matreya, and CDN Isotopes/QMX Laboratories. After lipid extraction,
samples were reconstituted in chloroform:methanol (1:2, v/v) and
synthetic external standards were post-extract spiked to the ex-
tracts. For quantiﬁcation of free cholesterol, an aliquot of each lipid
extract was treated with acetyl chloride to derivatize FC to modiﬁed
cholesteryl ester species according to Liebisch et al. [15]. The ex-
tracts were stored at 20 C prior to MS analysis.
3.2. Mass spectrometric analyses
In Shotgun lipidomics, lipid extracts were analysed on a hybrid
triple quadrupole/linear ion trap mass spectrometer (QTRAP 5500)
equipped with a robotic nanoﬂow ion source (NanoMate HD) ac-
cording to Ståhlman and colleagues [16]. Molecular lipids were
analysed in both positive and negative ion modes using multiple
precursor ion scanning (MPIS) and neutral loss scanning (NLS)
based methods [15,17,18].
Sphingolipids were analysed by reverse phase ultra-high pres-
sure liquid chromatography (UHPLC) using an Acquity BEH C18,
2.1 50 mm columnwith a particle size of 1.7 mm (Waters, Milford,
Massachusetts, USA). A 25 min gradient using 10 mM ammonium
acetate in water with 0.1% formic acid (mobile phase A) and 10 mM
ammonium acetate in acetonitrile:2-propanol (4:3, v/v) containing
0.1% formic acid (mobile phase B) was used. Sphingolipids were
monitored on a 4000 Q TRAP mass spectrometer (Applied Bio-
systems/MDS Analytical Technologies, Concord, Ontario, Canada)
equipped with an UHPLC system: CTC PAL autosampler (Leap
Technologies, Carrboro, NC, USA) and Rheos Allegro UHPLC (Flux
Instruments AG, Basel, Switzerland) using multiple reaction
monitoring (MRM) [19].
3.3. Data processing and quality controlling
The MS data ﬁles were processed using Lipid Proﬁler and
MultiQuant softwares for producing a list of lipid names and peak
areas. For each platform, a stringent cutoff was applied for sepa-
rating background noise from actual lipid peaks. Each sample was
controlled and only accepted when fulﬁlling the acceptance
criteria. Masses and counts of detected peaks were converted into a
list of corresponding lipid names. Lipids were normalized to their
respective internal standard and sample volume to retrieve their
concentrations. The concentrations of molecular lipids are pre-
sented as mM for plasma.
Quality control (QC) samples were utilized to monitor the
overall quality of the lipid extraction and mass spectrometry ana-
lyses [14]. The QC samples were mainly used to remove technical
outliers and lipid species that were detected below the lipid class
based lower limit of quantiﬁcation (LLOQ).
3.4. Statistical analyses
Wilcoxon rank-sum tests were conducted for comparing the
plasma lipid proﬁles of the three mouse genotype groups on
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lated by summing up the concentrations of corresponding mo-
lecular lipids averaged across the technical replicates. Statistical
analyses of the clinical samples were performed using the un-
paired Student t-test for LURIC dataset and paired t-test for
analysis of statin trial samples. A p < 0.05 was considered sig-
niﬁcant. All analyses are performed using SAS 9.2 (SAS
Institute).Fig. 1. Differences in lipid class median concentrations in plasma. Samples between the PCSK
and western diet (B). The signiﬁcance of a change is marked as *p  0.05, **p  0.01, and **
triacylglycerol; DAG, diacylglycerol; PC, phosphatidylcholine; PE, phosphatidylethanolam
lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC O, alkyl-linked phospha
dylethanolamine; PE P, alkenyl-linked phosphatidylethanolamine; SM, sphingomyelin; Ce
sphingosine; S1P, sphingosine-1-phosphate; SPA, sphinganine; SA1P, sphinganine-1-phosph4. Experimental results
4.1. PCSK9 deﬁciency resulted in reduction of the majority of lipid
classes in plasma and liver in mice on chow diet
In Pcsk9/ and Pcsk9þ/mice on regular chow diet a decrease in
most lipid classes was observed (Fig. 1A). In contrast, tri-
acylglycerols (TAG) were shown to be signiﬁcantly elevated by9/mice and wildtype and the PCSK9þ/ and wildtype mice on regular chow diet (A)
*p  0.001 for plasma samples (n  10). CE, cholesteryl ester; FC, free cholesterol; TAG,
ine; PI, phosphatidylinositol; PS, phosphatidylserine; PG, phosphatidylglycerol; LPC,
tidylcholine; PC P, alkenyl-linked phosphatidylcholine; PE O, alkyl-linked phosphati-
r, ceramide; Glc/GalCer, glucosyl/galactosylceramide; LacCer, lactosylceramide; SPH,
ate.
Fig. 2. Percentage differences in molecular lipid median concentrations in plasma of PCSK9/ mice on regular chow (A) and western (B) diet as compared to wildtype (WT).
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compared to the wild-type (Wt) mice. While most lipid changes in
Pcsk9þ/ mice were similar to the Pcsk9/ the phosphatidylcho-
line (PC), lysophosphatidylcholine (LPC), sphingosine-1-phosphate
(S1P), and sphinganine-1-phosphate (SA1P) levels did not decrease
in the heterozygote KO mice. The absolute concentration values for
each lipid class quantiﬁed in mouse plasma samples are presented
in Supplement Table 1.4.2. Western diet attenuated lipid lowering potency of PCSK9
deﬁciency
On Western diet, Pcsk9/ mice had only a small effect on
plasma lipids when summed up at the lipid class level. Major
changes in this setting were observed as signiﬁcant elevations in
sphingosine (SPH) and sphinganine (SPA) concentrations (Fig. 1B).
However, Pcsk9þ/mice demonstrated greater andmore signiﬁcant
plasma lipid responses to Western diet than Pcsk9/ mice. While
the SPH, SPA, S1P, and SA1P increased signiﬁcantly up to 67%, Cer,
glucosyl/galactosylceramides (Glc/GalCer), and LacCer decreased
from 25% to 44% in Pcsk9þ/ mouse plasma as compared to Wt
(Fig. 1B). Furthermore, elevated plasma cholesteryl ester (CE,þ40%)
and FC (þ21%) concentrations were recorded in Pcsk9þ/ mouse
plasma (Fig. 1B).4.3. Sphingolipids with short fatty acyl chains act as readout for
PCSK9 inhibition
Next, the effect of PCSK9 deﬁciency on molecular lipid species
was studied in order to evaluate whether lipid class level obser-
vations are applicable to all molecular lipid species, or whether
species speciﬁcity can be observed within each lipid class. In this
analysis, especially short chain fatty acid species such as palmitic
acid (C 16:0) containing sphingomyelin [SM(d18:1/16:0)], ceramide
[Cer(d18:1/16:0)], glucosyl/galactosylceramide [Glc/GalCer(d18:1/
16:0)], and lactosylceramide [LacCer(d18:1/16:0)] species appeared
as the most affected molecular lipid species in both Pcsk9/ andPcsk9þ/mice when the animals were on regular chow diet (Fig. 2,
respectively).
On Western diet a typical change in the plasma of PCSK9-
deﬁcient mice on Western diet appeared to be decreased Cer and
Glc/GalCer species with long fatty acyl chains such as the
Cer(d18:1/26:1), the Cer(d18:1/24:0), the Glc/GalCer(d18:1/26:1)
and the Glc/GalCer(d18:1/24:0) (Fig. 2).
4.4. Human PCSK9 loss-of-function carriers have lipid proﬁles
comparable to Pcsk9/ mice
Next, we investigated the translation of the mouse ﬁndings to
man. We analysed serum samples from human carriers of the
known loss-of-function variant in the PCSK9 gene (R46L, n ¼ 22).
This genetic variation resulted in a 10.1% non-signiﬁcant reduction
of plasma LDL-C in non-statin treated subjects as compared to
major allele carriers (Fig. 3). Intriguingly, the magnitude of reduc-
tion was much higher for many plasma molecular lipids species. In
these subjects, themost signiﬁcantly reduced lipid species included
the palmitic and stearic acid containing CE, Glc/GalCer, LacCer, and
SM species as observed also in the Pcsk9/ and Pcsk9þ/ mouse
models (Fig. 2). In contrast to PCSK9 KO mice, some cholesteryl
ester species including the CE 20:3 and the CE 20:4 were signiﬁ-
cantly reduced in fasting human serum due to the PCSK9-
deﬁciency (29% and 26%, respectively).
5. Discussion
In the present experimental setting, PCSK9-deﬁciency resulted
in decreased concentrations of a large variety of molecular lipid
species in mouse plasma, especially when mice were on regular
chow diet. Molecular lipidomic analyses of human serum from
subjects carrying the R46L loss-of-function mutation of the PCSK9
gene also showed substantial lipid species reductions. In particular,
distinct sphingolipid species were reduced by the PCSK9-deﬁciency
in both mouse and man. Based on these observations one could
suggest that there is an interaction between LDL receptor up-
regulation and the levels of circulating ceramides. This could be
Fig. 3. The percentage differences in molecular lipid median concentrations in serum of males (n ¼ 22) who carry the R46L variant of the PCSK9 gene in comparison to the major
allele carriers (n ¼ 966). Each point corresponds to a lipid molecule.
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Binding Protein 1 and 2 mediated gene transcription and
reduction in liver fatty acid synthesis due to increased hepatic
uptake of lipids via LDL receptors [20,21].
The short chain fatty acid containing glucosyl/galactosylcer-
amides, lactosylceramides, and sphingomyelins were good in-
dicators of PCSK9 deﬁciency. This suggests that the short chain fatty
acid containing sphingolipids, with the observed good translational
potency, could be used as sensitive readout of PCSK9 inhibition.
However, under high fat dietary conditions PCSK9 inhibition
seemed less efﬁcient and thus, it may be possible that dietary
factors and metabolic states affecting lipid metabolism may also
signiﬁcantly modify lipid lowering effects in patients treated with
PCSK9 inhibitors. Furthermore, we recorded signiﬁcant increases in
plasma TAG concentration due to PCSK9 deﬁciency in mouse
models. However, this was not reproduced in human carriers of the
loss-of-function mutation and, therefore, we believe that increase
in plasma TAG was speciﬁc to used animal model and cannot be
translated to human response to PCSK9 inhibition.
It should be remembered that the studied loss-of-function
mutation causes only modest reduction in plasma LDL-C levels
and therefore it is of importance to validate the present results by
analysing plasma of patients under treatment with PCSK9 in-
hibitors. Furthermore, the lipidomic proﬁles were evaluated in both
mice and humans with a genetic defect or mutation, which may
have induced some compensatory variation of genes involved in
lipid metabolism during the embryogenesis. Thus, the effect
observed in this sample does not necessarily reﬂect the effect that
might be expected to see in patients treated with PCSK9 inhibitors.
It is important to note that PCSK9 loss-of-function mutations
may confer cardiovascular protection on the carriers without
massive LDL-C reductions [6e8]. Thus, extreme LDL-C reductionsmay in fact not be needed as it may be equally important to
decrease plasma levels of low abundant, biologically active, mo-
lecular lipids such as distinct sphingolipids [7,8]. Similar ﬁndings
have earlier been reported by Meikle et al., who studied healthy
subjects, stable CAD patients and acute coronary syndrome pa-
tients [22]. They concluded that lipidomic markers may contribute
to a new approach to risk stratiﬁcation for unstable CAD. However,
another explanation to cardiovascular protection could be the
lifelong exposure to genetically pre-disposed low LDL-C levels in
PCSK9 loss-of-function mutation carriers [23].
In conclusion, PCSK9 inhibition results in diet dependant mo-
lecular lipid changes. Distinct sphingolipid species may be utilized
for characterizing novel compounds inhibiting PCSK9 and as sen-
sitive efﬁcacy markers of the PCSK9 inhibition.
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Plasma concentrations total lipid classes in wildtype, PCSK9 / and PCSK9þ/ mouse.
Lipid class Plasma
Regular chow Western
Concentration (mM) PCSK9/ vs. WT PCSK9þ/ vs. WT Concentration (mM) PCSK9/ vs. WT PCSK9þ/ vs. WT
WT PCSK9/ PCSK9þ/ p-value p-value WT PCSK9/ PCSK9þ/ p-value p-value
CE 2841.386 1589.193 2448.565 4.37E-06 1.52E-01 3545.175 3886.886 5087.397 3.79E-01 5.89E-02
FC 969.580 496.730 793.577 4.37E-06 4.42E-03 1315.276 1328.216 1594.682 4.73E-01 5.78E-01
TAG 252.737 409.153 397.970 3.23E-02 219.778 277.465 2.30E-01
PC 2231.956 1567.526 2243.219 8.64E-06 4.58E-01 2681.466 3083.042 3440.220 3.79E-01 1.47E-01
PE 8.537 7.490 8.633 2.41E-01 9.70E-01 6.459 7.132 6.652
PI 24.223 14.666 21.235 3.88E-04 2.62E-01 24.918 30.694 26.535 2.41E-01 5.39E-01
PC P 5.507 3.666 4.670 5.19E-01 12.255 9.086 10.145 2.36E-01 4.63E-01
LPC 491.050 401.294 507.409 1.23E-02 7.43E-01 459.511 508.983 547.066 3.79E-01 1.63E-01
LPE 4.675 3.278 5.409 1.53E-01 8.04E-01 4.455 2.656 4.221 8.94E-01
SM 69.540 38.686 56.202 1.42E-05 1.81E-02 60.252 53.032 72.552 2.73E-01 4.64E-01
Cer 5.034 3.157 3.936 2.64E-05 7.21E-02 7.894 6.263 4.487 1.30E-01 1.36E-03
Glc/GalCer 9.731 4.718 7.387 1.22E-05 7.89E-03 17.899 15.972 9.949 3.42E-01 3.40E-03
LacCer 0.190 0.110 0.155 8.42E-07 3.06E-02 0.319 0.298 0.239 1.93E-01 9.26E-04
SPH 0.143 0.171 0.151 2.15E-01 9.08E-01 0.139 0.197 0.229 1.51E-02 2.81E-05
S1P 0.076 0.068 0.082 2.01E-01 1.00Eþ00 0.064 0.077 0.106 1.49E-01 9.07E-05
SPA 0.023 0.021 0.018 9.18E-01 5.20E-01 0.021 0.031 0.034 2.21E-02 1.42E-04
SA1P 0.003 0.002 0.003 7.57E-01 9.34E-01 0.003 0.003 0.004 2.45E-01 1.42E-04References
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